MOTS-c side effects have not been characterised in any completed human trial. In its May 2026 evaluation of the peptide for the pharmacy compounding bulk-substances list, the FDA reported that it identified no clinical studies and no human exposure data for MOTS-c by any route of administration, and no pharmacokinetic data in people. A search of the agency's adverse-event database returned no reports at all, which says more about the reporting system than about the peptide. What can honestly be said comes from three places: what is observed with injected peptides of this kind, what the pharmacology implies, and what a prescriber screens for before writing anything.
What the evidence on MOTS-c side effects actually is
The FDA's briefing document for the July 2026 Pharmacy Compounding Advisory Committee meeting is the most complete safety appraisal of this peptide in existence, and most of it is an inventory of what is missing (FDA briefing document, May 2026).
| Evidence a side-effect profile normally rests on | What the FDA review found |
|---|---|
| Clinical studies of administered MOTS-c | None identified, by any route |
| Human pharmacokinetic data | None identified |
| Nonclinical toxicity studies | None identified |
| Developmental and reproductive toxicity studies | None identified |
| Carcinogenicity studies | None identified |
| Adverse-event reports through 9 March 2025 | None retrieved |
MOTS-c is not a component of any FDA-approved drug product, so there is no label, no approved indication and no post-marketing surveillance to build a side-effect list from. The review added two details that matter for interpreting anything a person feels after a dose: the molecular targets behind MOTS-c's effects remain unknown, which makes it difficult to predict which organs a dose acts on, and an in-vitro study found the peptide is rapidly broken down in human blood.
The committee went on to vote 7 to 5, with 2 abstentions, to recommend MOTS-c for the section 503A bulk substances list, against the agency staff's own proposal to leave it off (PCAC meeting, 23-24 July 2026). Those votes are advisory and rulemaking has not concluded. A licensed provider may still prescribe a compounded formulation where they judge it appropriate; that decision is between the patient and the doctor.
Injection-site reactions, the one effect consistently reported
Two lines of human evidence bear on this, and neither of them is MOTS-c itself.
CB4211, a MOTS-c analogue developed by CohBar, is the closest this peptide family has come to a sponsored clinical programme. In November 2018 the company suspended its Phase 1 study to address injection-site reactions that were mild but, in its own words, unexpectedly persistent. Its chief scientific officer described painless bumps felt under the skin, with some of the dose apparently remaining where it was injected, and noted that mild injection-site reactions are common in Phase 1 studies of subcutaneously injected peptides (CohBar, 5 November 2018). Dosing later resumed, and the Phase 1a/1b study completed with 88 participants.
SS-31 (elamipretide) and MOTS-c are both mitochondrial-targeted peptides given by subcutaneous injection, and elamipretide is the one compound in that category with large placebo-controlled human safety data. In MMPOWER-3, a phase 3 trial in which 218 adults received 40 mg daily or placebo for 24 weeks, adverse events were reported by 98.2% of those on elamipretide against 76.1% on placebo, and the adverse events occurring above 10% frequency were injection-site reactions: erythema, itching, pain, swelling, induration, bruising, bleeding, urticaria and nodules. Serious adverse events were uncommon in both arms, 4.6% against 2.8% (Karaa et al., Neurology 2023). Our overview of SS-31 covers that compound in its own right.
Neither figure is a MOTS-c rate. What they establish is the base rate for the route and the format: a subcutaneous peptide injection frequently produces something visible where the needle went, and that is the effect most likely to be met first.
What is theoretical, and why theoretical does not mean absent
The FDA review's principal unquantified concern is immunogenicity. Peptides can aggregate, aggregation is a recognised risk factor for an immune response, subcutaneous injection is associated with more immunogenicity than the intravenous route, and no study has assessed aggregation or immunogenicity for compounded MOTS-c preparations. The possible consequences run from antibodies with no clinical sign at all through to reactions that matter, and they are not predictable in advance.
The metabolic pharmacology points at one specific interaction. MOTS-c activates AMPK and prevented diet-induced and age-dependent insulin resistance in mice (Lee et al., Cell Metabolism 2015). Anything that increases insulin sensitivity is a question for someone already taking insulin or a sulfonylurea, where the glucose-lowering effects would add together. That is reasoning from mechanism, not a measured rate.
The deeper problem is that without a controlled trial there is no placebo arm, so an effect that appears after an injection cannot be separated from ordinary day-to-day variation, from expectation, or from the particular preparation rather than the peptide in it. It is also why dose-related effects cannot be mapped: as MOTS-c dosage sets out, there is no established human dose to relate them to, and the proposed uses covered in MOTS-c benefits rest on the same animal literature.
Who a prescriber screens out
With no label to prescribe from, screening is judgment rather than a checklist. What a provider weighs before considering MOTS-c:
- Pregnancy or breastfeeding. No developmental or reproductive toxicity studies exist for this peptide, so there is nothing to reason from, which is itself the answer.
- Insulin or a sulfonylurea, and diabetes management generally, for the additive glucose effect described above.
- A history of cancer. No carcinogenicity studies have been done and the molecular targets are unmapped; that combination is a reason for caution rather than a documented risk.
- Previous reactions to injected medicines, including persistent injection-site nodules.
- Whether the request is clinically coherent at all. A compound with no established human dose is a poor answer to a symptom nobody has worked up.
Through Promise, MOTS-c is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider reviews every request and prescribes only where MOTS-c is appropriate for the person asking, and not everyone qualifies.
Why "no reported side effects" means the absence of data
This is the line to read carefully on any page selling this peptide. The FDA retrieved no adverse-event reports for MOTS-c and, in the same document, recorded why: pharmacies compounding under section 503A generally do not report adverse events to the agency, so unless someone files a report the agency may never learn of one. Nothing was being collected. That is not the same as nothing happening.
There is a second reason to distrust a quiet safety page. A vial bought without a prescription is not made to dispensing standards, and its contents are frequently not what the label says. When researchers test-purchased semaglutide vials from illegal online pharmacies selling without a prescription, measured purity ran between 7.7% and 14.37% against the 99% claimed on the labels, and bacterial endotoxin was present in every sample tested (Ashraf et al., J Med Internet Res 2024). A reaction after injecting something like that may have nothing to do with the peptide named on the box. We cover that market in can you buy peptides over the counter.
An honest page about this compound ends up saying the same thing twice. The reported side effects are few because almost nothing has been measured, and the sane response to that is a prescriber who knows your history, a preparation made by a licensed pharmacy, and somebody to tell when something changes.